查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844144

食品过敏诊断和治疗市场（按产品类型、过敏原类型、最终用户和分销管道划分）—2025-2032年全球预测

Food Allergy Diagnostics & Therapeutics Market by Product Type, Allergen Type, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，食品过敏诊断和治疗市场规模将达到 145.7 亿美元，复合年增长率为 10.75%。

主要市场统计数据
基准年 2024 64.3亿美元
预计年份：2025年 71.4亿美元
预测年份：2032年 145.7亿美元
复合年增长率 (%) 10.75%

本书简明扼要地介绍了食物过敏诊断和治疗方法领域的最新进展，重点关注患者预后、技术创新和政策驱动因素。

食品过敏诊断和治疗领域正经历结构性发展，这主要得益于临床创新、护理模式的转变以及支付方和监管机构日益增长的关注。能够更精准地识别致敏模式的诊断技术正与旨在实现持续免疫调节的治疗方法相融合，从而创造了一个临床医生、实验室技术人员和行业合作伙伴必须比以往任何时候都更加紧密合作的环境。

随着临床界广泛采用成分解析诊断和居家筛检，治疗方法策略正从控制症状转向缓解疾病疗法。这两大趋势迫使相关人员重新评估临床路径、实证策略和商业模式。未来成功的倡议将整合严格的临床检验、包含医保支付方参与的卫生经济学原理以及以患者为中心的清晰价值提案，从而将实验室技术的进步转化为更佳的治疗效果和更高效的医疗服务。

识别影响诊断和治疗管道的临床实践、技术应用、支付方参与和患者行为方面的变革性转变

近年来，过敏症的诊疗和商业化模式正经历许多重大曲折点。多重检测和分子成分诊断等治疗技术的进步，为临床医生提供了详细的过敏原信息，有助于精准治疗；同时，数位化工具和远端检测也拓展了筛检和长期监测的范围。此外，治疗方法也不断多样化。儘管传统的抗组织胺和急性干预措施仍然是治疗的基石，但免疫疗法和生技药品正推动治疗模式转向长期疾病管理。

随着技术和临床实践的变革，支付方框架和监管预期也在不断演变，迫使相关人员证明其真正的益处和成本效益。便利性、安全性和生活品质的显着改善正在推动患者接受新技术。总而言之，这些变化共同表明，整合策略对于技术的可持续应用和患者疗效的显着改善至关重要。

评估2025年美国关税对供应链、试剂采购、临床检测、定价策略和国际合作的影响

2025年生效的政策措施将导致关税上调和关税结构调整，这对从事过敏诊断和治疗的製造商、经销商和临床实验室将带来重要考量。在涉及专业试剂、检测组件和生技药品成分跨境运输的供应链中，其影响将最为显着。随着运输管道日益复杂，采购团队正在重新调整筹资策略的风险，并确保供应的连续性。

临床试验申办方和研究机构都在调整试验方案和预算，以因应进口材料和外包检测服务可能带来的成本上涨。这些调整通常包括儘早与生产合作伙伴接洽、考虑区域性生产方案以及重视库存规划。商业团队也在根据需要重新调整定价和合约条款。同时，支付方也积极参与讨论高成本产品和新技术对报销的影响。此外，优先考虑供应链多元化、加强供应商合约以及加快关键投入品的在地化进程，有助于减轻关税带来的衝击，并确保研发和交付按时完成。

深入洞察产品类型、过敏原类别、最终用户和分销管道等关键细分因素将如何推动临床应用和商业策略的发展。

透过从产品类型、过敏原特异性、终端用户环境和分销管道等角度审视市场，細項分析能够揭示可操作的洞察。诊断测试包括家庭过敏测试、成分特异性诊断、皮肤点刺试验和特异性IgE测试，每种测试都有不同的临床效用和普及程度，会影响实验室工作流程和照护现场决策。虽然抗组织胺和急性期护理仍然是治疗的关键，但经经皮、口服和皮下途径给药的免疫疗法与单株抗体一起构成了长期治疗模式，每种疗法都需要量身定制的实证策略。

鸡蛋、牛奶、花生、坚果、贝类、芝麻、大豆、鱼类和小麦过敏在诊断、病患教育需求和治疗耐受性方面各有不同。包括医院实验室、照护现场(POC) 机构、参考文献实验室和研究机构在内的终端用户，在伴随诊断的采购行为、技术能力和偏好也存在差异。此外，包括诊所和诊断中心、医院、线上平台和病人历程的分销管道，决定了患者的就诊途径和商业模式。整合这些细分资讯有助于制定与临床工作流程和病患就诊路径相契合的产品定位、证据产生和市场策略的策略决策。

透过对美洲、欧洲、中东和非洲以及亚太地区监管、报销和市场动态的洞察

区域动态对诊断和治疗创新技术的研发、应用和报销方式有显着影响。美洲地区临床研究持续活跃，并展现出多元化的商业模式，强调在门诊和住院环境中快速整合新的诊断方法和专科治疗。相较之下，欧洲、中东和非洲的监管和报销体係错综复杂，各国之间存在着协调努力和差异，因此需要有针对性的证据整合和区域性定价策略。

亚太地区是一个多元化的区域，拥有高产能的製造地和快速发展的患者准入计划，该地区的各项工作通常围绕监管协调、技术转移和可扩展的分销解决方案展开。在亚太地区，跨境研究合作、监管协调以及对本地临床能力的投资是普遍存在的趋势，这些都有助于扩大应用范围并增强供应链的韧性。了解这些区域差异对于调整商业化策略以及优先投资于监管和支付方合作至关重要。

深入剖析诊断和治疗领域主要企业领导企业的竞争格局、策略伙伴关係、研发投资和优先事项。

主要企业之间的竞争动态呈现出差异化的产品组合、策略伙伴关係以及针对性研发投入的特征。一些公司专注于多重诊断平台和分子水平检测，以实现更精准的患者分层；而另一些公司则优先开发旨在改变疾病进程的免疫疗法和生技药品。随着整合医疗模式需要统一的证据和协作式的研发路径，诊断创新者和治疗药物开发商之间的合作也日益普遍。

投资策略体现了近期商业性优先事项与长期产品线开发之间的平衡。策略伙伴关係，包括经销协议、研发合作和授权协议，能够加速取得互补能力。营运重点通常在于增强生产韧性、确保试剂供应以及实施可扩展的品质系统以满足多样化的监管要求。在临床和物流可靠性至关重要的市场中，能够清晰传达临床价值、使证据产生与支付方需求相符并建立可互通的临床工作流程的相关人员将获得竞争优势。

建议领导者加快患者就医速度、优化供应链、与支付方合作，并优先考虑过敏治疗领域具有影响力的创新。

该领域的领导者应采取一系列务实且以患者为中心的措施，将创新转化为可近的医疗服务。首先，在研发早期阶段就应使证据产生与支付方和监管机构的期望保持一致，确保临床检验、卫生经济学和真实世界证据的收集能够支持报销和製剂配方方面的讨论。其次，透过关键试剂供应商多元化、评估区域生产方案以及建立紧急库存来优化供应链策略，从而降低贸易政策波动带来的风险。

第三，优先考虑互通性和临床医生参与，设计能够无缝融入现有临床工作流程并提供清晰决策支援的诊断和治疗方法方案。第四，投资于病患教育和支援服务，以提高病患对免疫疗法的依从性，并确保居家检测的安全合理使用。最后，寻求选择性的伙伴关係，以加速市场准入并扩大地域覆盖范围，同时保持核心技术优势。结合这些步骤，企业能够有效管理风险、加速产品推广，并向临床医生、支付者和患者展现可衡量的价值。

一套透明的调查方法，详细阐述了资料来源、调查方法和资料来源、检验步骤以及伦理考量，能够提供可靠的产业洞察。

本调查方法基于结构化流程，结合了主要相关利益者参与、严谨的二次综合分析和迭代检验。主要资讯来源包括与临床医生、实验室主任、公司高管、支付方和患者权益倡导代表的访谈和咨询，以确保研究结果反映现实世界的决策因素。二次综合分析则利用同行评审文献、监管指南、临床试验註册库和公开的技术信息，为主要见解提供背景信息。

分析方法包括定性主题分析、跨细分维度的比较评估以及基于情境的供应炼和政策影响评估。检验步骤包括与专家最后覆核关键结论，并透过三角测量法协调不同观点。出于伦理考量，访谈资料已匿名化处理，且研究限制已明确说明。这些方法的结合确保了分析结果的稳健性、可操作性，并与临床、商业和政策领域密切相关。

区域结论：摘要对相关人员的影响，并重点介绍能够推进创新路径、提升营运韧性和改善病患预后的合作模式。

所审查的证据表明，过敏诊断和治疗的持续进步依赖于技术开发、证据生成、供应链韧性和相关人员参与等多方面的协调努力。诊断准确性有助于更好地对患者进行分层，而多样化的治疗方法则为从症状控制转向疾病改善提供了契机。同时，监管和报销方面的实际情况要求有针对性的证据和与支付方的积极沟通，才能实现常规临床应用。

展望未来，拥有整合跨职能规划（包括临床检验、切实可行的部署管道和以患者为中心的支援）的组织，将更有能力将创新转化为可衡量的成果。产业、临床系统和政策相关人员之间的合作对于克服与医疗服务可近性、医疗负担能力和营运复杂性相关的障碍仍然至关重要。在此背景下，清晰的策略重点和严谨的执行将决定倡议能带来最大的临床和商业性价值。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大多重免疫检测平台规模，用于同时检测多种食物过敏原特异性IgE生物标记物
  • 生技创新企业与领先製药公司扩大策略联盟，推动花生过敏脱敏口服免疫疗法
  • 将数位健康应用程式与穿戴式感测器技术结合，即时监测食物过敏情况。
  • 增加对重组低过敏性蛋白疫苗和针对主要食物过敏原的胜肽免疫疗法的投资
  • 采用次世代定序技术对儿科病患的个别过敏致敏模式进行全面分析

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 按产品类型分類的食物过敏诊断和治疗市场

  • 诊断测试
    • 家用过敏测试
    • 组件解决方案诊断
    • 皮肤点刺试验
    • 特异性IgE检测
  • 治疗产品
    • 抗组织胺药
    • 紧急治疗
    • 免疫疗法
      • 表皮免疫疗法
      • 口服免疫疗法
      • 皮下免疫疗法
    • 单株抗体

9. 按过敏原类型分類的食物过敏诊断与治疗市场

  • 鸡蛋过敏
  • 鱼类过敏
  • 牛奶过敏
  • 花生过敏
  • 芝麻过敏
  • 贝类过敏
  • 大豆过敏
  • 树坚果过敏
  • 小麦过敏

第十章：按最终用户分類的食物过敏诊断和治疗市场

  • 医院检查室
  • 照护现场环境
  • 参考实验室
  • 研究所

11. 按分销管道分類的食物过敏诊断和治疗市场

  • 诊所和诊断中心
  • 医院
  • 在线的
  • 药局

12. 各地区食物过敏诊断及治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：按群体分類的食物过敏诊断和治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国食物过敏诊断及治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Quest Diagnostics Incorporated
    • Eurofins Scientific SE
    • bioMerieux SA
    • Abbott Laboratories
    • Nestle Health Science SA
    • ALK-Abello A/S
    • DBV Technologies SA
    • Stallergenes Greer International SA
    • Aimmune Therapeutics LLC
Product Code: MRR-ED54C46E8118

The Food Allergy Diagnostics & Therapeutics Market is projected to grow by USD 14.57 billion at a CAGR of 10.75% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.43 billion
Estimated Year [2025] USD 7.14 billion
Forecast Year [2032] USD 14.57 billion
CAGR (%) 10.75%

A concise introduction to the evolving food allergy diagnostics and therapeutics landscape emphasizing patient outcomes, innovation, and policy drivers

The food allergy diagnostics and therapeutics sector is experiencing a period of structured advancement driven by clinical innovation, changing care models, and intensified attention from payers and regulators. Diagnostic technologies that enable more precise identification of sensitization patterns are converging with therapeutic approaches that seek durable immune modulation, producing an environment in which clinicians, laboratorians, and industry partners must coordinate more closely than ever before.

As the clinical community adopts component-resolved diagnostics and at-home screening options, therapeutic pipelines are simultaneously shifting from symptom control toward disease-modifying approaches. This dual movement compels stakeholders to reassess clinical pathways, evidence generation strategies, and commercial models. Moving forward, successful initiatives will integrate rigorous clinical validation, payer-engaged health economic rationale, and clear patient-centered value propositions to translate laboratory advances into improved outcomes and more efficient care delivery.

Identifying transformative shifts in clinical practice, technology adoption, payer engagement, and patient behavior reshaping diagnostic and therapeutic routes

Recent years have seen multiple inflection points that collectively redefine how allergy care is delivered and commercialized. Technological advances such as multiplexed assays and molecular component diagnostics are providing clinicians with granular profiles that inform precision treatment, while digital tools and remote testing expand the reach of screening and longitudinal monitoring. Concurrently, therapeutic approaches have diversified: traditional antihistamines and emergency interventions remain foundational, but immunotherapy modalities and biologic agents are prompting shifts toward long-term disease management.

Alongside technology and clinical practice changes, payer frameworks and regulatory expectations are evolving, pressing stakeholders to demonstrate real-world benefits and cost-effectiveness. Patient expectations are also a powerful driver; convenience, safety, and measurable improvements in quality of life are guiding uptake. Taken together, these shifts create a landscape in which integrated strategies across diagnostics, therapeutics, and care delivery models are essential for sustainable adoption and meaningful improvements in patient outcomes.

Assessing impact of US tariffs from 2025 on supply chains, reagent sourcing, clinical trials, pricing strategies and international collaboration

Policy actions implemented in 2025 that increase or alter tariff structures have introduced material considerations for manufacturers, distributors, and clinical laboratories engaged in allergy diagnostics and therapeutics. The effects are most visible along supply chains where specialized reagents, assay components and biologic drug ingredients cross borders. As shipping paths become more complex, procurement teams are reallocating sourcing strategies to reduce exposure to tariff volatility and to preserve continuity of supply.

Clinical trial sponsors and research institutions are likewise adapting protocols and budgets to accommodate potential cost escalations associated with imported materials or outsourced testing services. These adjustments frequently involve earlier engagement with manufacturing partners, consideration of regional manufacturing alternatives, and a heightened focus on inventory planning. Commercial teams are reallocating pricing and contracting levers when necessary, while payers are being engaged proactively to discuss the implications for reimbursement of higher-cost products or new technologies. In the near term, organizations that prioritize supply chain diversification, strengthen supplier agreements, and accelerate localization of key inputs will be better positioned to mitigate tariff-induced disruptions and sustain development and delivery timelines.

Key segmentation insights on how product types, allergen categories, end users and distribution channels drive clinical uptake and commercial strategy

Segmentation analysis reveals practical insights when examined through the lens of product type, allergen specificity, end-user setting, and distribution pathway. Diagnostic tests encompass at-home allergy tests, component resolved diagnostics, skin prick tests, and specific IgE tests, each presenting distinct clinical utility and adoption profiles that influence laboratory workflows and point-of-care decision making. Therapeutic products include antihistamines and emergency treatments that remain essential, while immunotherapy-delivered via epicutaneous, oral, or subcutaneous routes-together with monoclonal antibodies shape the longer-term management paradigm and demand tailored evidence strategies.

Allergen type introduces further nuance: egg, milk, peanut, tree nut, shellfish, sesame, soy, fish, and wheat allergies present different diagnostic challenges, patient education needs, and therapy tolerability considerations. End users such as hospital laboratories, point-of-care settings, reference laboratories, and research institutes exhibit varying procurement behaviors, technical capabilities and preferences for companion diagnostics. Finally, distribution channels including clinics and diagnostic centers, hospitals, online platforms and pharmacies determine patient access pathways and commercial models. Integrating these segmentation dimensions supports strategic decisions about product positioning, evidence generation, and go-to-market approaches that align with clinical workflows and patient journeys.

Regional insights on how the Americas, Europe, Middle East & Africa and Asia-Pacific present distinct regulatory, reimbursement and market dynamics globally

Regional dynamics materially influence how diagnostic and therapeutic innovations are developed, adopted, and reimbursed. The Americas continue to demonstrate robust clinical research activity and a diverse set of commercial models that emphasize rapid integration of new diagnostics and specialty therapeutics in both ambulatory and hospital settings. In contrast, Europe, Middle East & Africa offer a complex regulatory and reimbursement mosaic where harmonization efforts coexist with country-level variability, requiring targeted evidence packages and localized pricing strategies.

Asia-Pacific presents a heterogeneous mix of high-capacity manufacturing hubs and rapidly expanding patient access initiatives; engagement in this region often centers on regulatory alignment, technology transfer, and scalable distribution solutions. Across all regions, cross-border collaboration in research, harmonized regulatory interactions, and investment in local clinical capacity are recurring themes that enable broader adoption and more resilient supply chains. Understanding these regional differences is essential for calibrating commercialization efforts and prioritizing investment in regulatory and payer engagement.

Key companies insights on competitive positioning, strategic partnerships, R&D investment and priorities among diagnostic and therapeutic leaders

Competitive dynamics among leading companies in diagnostics and therapeutics are characterized by differentiated portfolios, strategic partnerships, and targeted investment in research and development. Some firms are concentrating on multiplexed diagnostic platforms and molecular-level assays to enable more precise patient stratification, while others prioritize development of immunotherapies and biologics designed to alter disease trajectory. Collaboration between diagnostic innovators and therapeutic developers is increasingly common as integrated care models require aligned evidence and co-development pathways.

Investment strategies reflect a balance between near-term commercial priorities and long-term pipeline development. Strategic partnerships-including distribution agreements, R&D collaborations and licensing arrangements-are accelerating access to complementary capabilities. Operational priorities often focus on strengthening manufacturing resilience, securing reagent supply, and implementing scalable quality systems to meet diverse regulatory requirements. Stakeholders that clearly communicate clinical value, align evidence generation with payer needs, and establish interoperable clinical workflows gain advantage in a market where clinical credibility and logistical reliability matter most.

Recommendations for leaders to accelerate patient access, optimize supply chains, align with payers, and prioritize impactful innovation for allergy care

Leaders in the field should adopt a pragmatic and patient-centered set of actions to translate innovation into accessible care. First, align evidence generation with payer and regulatory expectations early in development so that clinical validation, health economics and real-world evidence collection support reimbursement and formulary discussions. Second, optimize supply chain strategies by diversifying suppliers for critical reagents, evaluating regional manufacturing options, and establishing contingency inventory to reduce exposure to trade-policy fluctuations.

Third, prioritize interoperability and clinician engagement by designing diagnostics and therapy introduction programs that fit seamlessly into existing clinical workflows and deliver clear decision support. Fourth, invest in patient education and support services to improve adherence with immunotherapy regimens and to ensure safe, appropriate use of at-home testing. Finally, pursue selective partnerships that accelerate market entry and expand geographic footprint without diluting core technical competencies. Taken together, these steps help organizations manage risk, accelerate uptake, and demonstrate measurable value to clinicians, payers and patients.

Transparent research methodology outlining data sources, analytical approaches, validation steps, and ethical considerations to produce robust industry insights

This research is grounded in a structured methodology that combines primary stakeholder engagement, rigorous secondary-source synthesis, and iterative validation. Primary inputs include interviews and consultations with clinicians, laboratory directors, commercial executives, payers, and patient advocacy representatives to ensure findings reflect real-world decision drivers. Secondary synthesis draws on peer-reviewed literature, regulatory guidance, clinical trial registries and publicly available technical information to contextualize primary insights.

Analytical approaches incorporate qualitative thematic analysis, comparative assessment across segmentation dimensions, and scenario-based evaluation of supply chain and policy impacts. Validation steps include cross-checking key conclusions with subject-matter experts and reconciling divergent perspectives through triangulation. Ethical considerations guide anonymization of interview data and the transparent representation of limitations. This combination of methods ensures the analysis is robust, actionable, and relevant to clinical, commercial and policy audiences.

Regional conclusion summarizing implications for stakeholders, emphasizing innovation pathways, operational resilience, collaborative models advancing patient outcomes

The body of evidence examined indicates that sustained progress in allergy diagnostics and therapeutics depends on coordinated efforts across technological development, evidence generation, supply chain resilience and stakeholder engagement. Diagnostic precision enables better patient stratification, while diversified therapeutic modalities offer opportunities to shift from symptom control to disease modification. At the same time, regulatory and reimbursement realities require targeted evidence and constructive payer engagement to achieve routine clinical adoption.

Looking ahead, organizations that integrate cross-functional planning-combining clinical validation, pragmatic deployment pathways, and patient-centered support-will be best placed to convert innovation into measurable outcomes. Collaboration across industry, clinical systems and policy stakeholders will remain essential for overcoming barriers related to access, affordability and operational complexity. In this context, clear strategic priorities and disciplined execution will determine which initiatives deliver the greatest clinical and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of multiplexed immunoassay platforms for simultaneous detection of multiple food allergen specific IgE biomarkers
  • 5.2. Growing strategic collaborations between biotech innovators and big pharma to advance oral immunotherapy for peanut allergy desensitization
  • 5.3. Integration of digital health applications and wearable sensor technologies for real-time monitoring of allergic reactions to food intake
  • 5.4. Rising investment in recombinant hypoallergenic protein vaccines and peptide-based immunotherapies targeting major food allergens
  • 5.5. Adoption of next-generation sequencing technologies for comprehensive profiling of individual allergic sensitization patterns in pediatric patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Food Allergy Diagnostics & Therapeutics Market, by Product Type

  • 8.1. Diagnostic Tests
    • 8.1.1. At-Home Allergy Tests
    • 8.1.2. Component Resolved Diagnostics
    • 8.1.3. Skin Prick Tests
    • 8.1.4. Specific IgE Tests
  • 8.2. Therapeutic Products
    • 8.2.1. Antihistamines
    • 8.2.2. Emergency Treatments
    • 8.2.3. Immunotherapy
      • 8.2.3.1. Epicutaneous Immunotherapy
      • 8.2.3.2. Oral Immunotherapy
      • 8.2.3.3. Subcutaneous Immunotherapy
    • 8.2.4. Monoclonal Antibodies

9. Food Allergy Diagnostics & Therapeutics Market, by Allergen Type

  • 9.1. Egg Allergy
  • 9.2. Fish Allergy
  • 9.3. Milk Allergy
  • 9.4. Peanut Allergy
  • 9.5. Sesame Allergy
  • 9.6. Shellfish Allergy
  • 9.7. Soy Allergy
  • 9.8. Tree Nut Allergy
  • 9.9. Wheat Allergy

10. Food Allergy Diagnostics & Therapeutics Market, by End User

  • 10.1. Hospital Laboratories
  • 10.2. Point-Of-Care Settings
  • 10.3. Reference Laboratories
  • 10.4. Research Institutes

11. Food Allergy Diagnostics & Therapeutics Market, by Distribution Channel

  • 11.1. Clinics & Diagnostic Centers
  • 11.2. Hospitals
  • 11.3. Online
  • 11.4. Pharmacies

12. Food Allergy Diagnostics & Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Food Allergy Diagnostics & Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Food Allergy Diagnostics & Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.2. Quest Diagnostics Incorporated
    • 15.3.3. Eurofins Scientific SE
    • 15.3.4. bioMerieux SA
    • 15.3.5. Abbott Laboratories
    • 15.3.6. Nestle Health Science S.A.
    • 15.3.7. ALK-Abello A/S
    • 15.3.8. DBV Technologies S.A.
    • 15.3.9. Stallergenes Greer International S.A.
    • 15.3.10. Aimmune Therapeutics LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AT-HOME ALLERGY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AT-HOME ALLERGY TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AT-HOME ALLERGY TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AT-HOME ALLERGY TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AT-HOME ALLERGY TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AT-HOME ALLERGY TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN PRICK TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN PRICK TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN PRICK TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN PRICK TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN PRICK TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN PRICK TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIFIC IGE TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIFIC IGE TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIFIC IGE TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIFIC IGE TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIFIC IGE TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIFIC IGE TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGENCY TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGENCY TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGENCY TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGENCY TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGENCY TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGENCY TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EGG ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EGG ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EGG ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EGG ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EGG ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EGG ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FISH ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FISH ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FISH ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FISH ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FISH ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FISH ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILK ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILK ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILK ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILK ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILK ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILK ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEANUT ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEANUT ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEANUT ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEANUT ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEANUT ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEANUT ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SESAME ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SESAME ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SESAME ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SESAME ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SESAME ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SESAME ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SHELLFISH ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SHELLFISH ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SHELLFISH ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SHELLFISH ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SHELLFISH ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SHELLFISH ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOY ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOY ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOY ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOY ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOY ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOY ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREE NUT ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREE NUT ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREE NUT ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREE NUT ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREE NUT ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREE NUT ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY WHEAT ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY WHEAT ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY WHEAT ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY WHEAT ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY WHEAT ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY WHEAT ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA FOOD ALL